Interventional Cardiology

SCAI 2020: Guidelines, Position Statements, and More

SCAI 2020: Guidelines, Position Statements, and More

The Society for Cardiovascular Angiography and Interventions (SCAI), holding its annual meeting virtually due to the COVID-19 pandemic, recently released several position statements and...
GI Cancers More Common in NOAC-treated AFib Patients

Off-label Use of Oral Anticoagulants Raises Ischemic Stroke Risk: Study

New research published in JAMA Cardiology indicates that the use of direct oral anticoagulants for left ventricular (LV) thrombi are linked with an increased...
COVID-19 and Fatal Outcomes for Cardiovascular Disease: A Wuhan Cohort Study

COVID-19 and Fatal Outcomes for Cardiovascular Disease: A Wuhan Cohort Study

Underlying cardiovascular disease was not necessarily linked with fatal outcomes in patients with COVID-19, while myocardial injury was, a new study suggests. "Increasing numbers of...
COVID-19 anticoagulants

Cardio Round-up: COVID-19 Consumes the World, and Cardiologists Must Be Ready

This COVID-19 edition of Cardio Round-up features some research on various cardiology-related topics being encountered during the pandemic. Cardiac Injury and Death in COVID-19 Patients...
Implant Depth in TAVR Procedures Influences Outcomes Reporting

Implantation Depth in TAVR Procedures Influences Outcomes Reporting: Study

Optimal implant depth (OID) during transcatheter aortic valve replacement (TAVR) occurs about a third of the time, a new study indicates. The authors, seeking to...
ECPR Linked With Preserved Neurological Functions in Some Patients

Extracorporreal CPR Linked With Preserved Neurological Functions in Some Patients: CRITICAL Study

Extracorporeal cardiopulmonary resuscitation (ECPR) may be a viable option for patients who do not respond to traditional CPR, a new analysis suggests. "Standard CPR uses...
Rivaroxaban Plus Aspirin Lowers Vs. Aspirin Alone in Those With Prior PCI

COMPASS-PCI: Rivaroxaban Plus Aspirin Lowers MACE Better Than Aspirin Alone in Those With Prior...

Highlights The COMPASS trial showed that dual pathway inhibition with rivaroxaban plus aspirin was better at reducing major cardiovascular endpoints than aspirin alone. This...

Curated Journal Reading List